Highlights of This Issue 4417

SPECIAL FEATURES

CCR Translations

4419  TP53 Mutations and Lung Cancer: Not All Mutations Are Created Equal
Ramaswamy Govindan and Jason Weber
See related article, p. 4647

4422  “Companion Diagnostics”: Has Their Time Come and Gone?
Fred R. Hirsch, Paul A. Bunn Jr, and Roy S. Herbst
See related article, p. 4488

CCR New Strategies

4425  New Strategies in Personalized Medicine for Solid Tumors: Molecular Markers and Clinical Trial Designs
Juliane M. Jürgensmeier, Joseph P. Eder, and Roy S. Herbst

CCR Perspectives in Drug Approval

4436  FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer

Molecular Pathways

4442  Molecular Pathways: Targeting ETS Gene Fusions in Cancer
Felix Y. Feng, J. Chad Brenner, Maha Hussain, and Arul M. Chinnaiyan

CANCER THERAPY: CLINICAL

4449  Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (GSK2118436)

4459  p53MVA Therapy in Patients with Refractory Gastrointestinal Malignancies Elevates p53-Specific CD8+ T-cell Responses
Nicola R. Hardwick, Mary Carroll, Teodora Kalcheva, Dajun Qian, Dean Lim, Lucille Leong, Peiguo Chu, Joseph Kim, Joseph Chao, Marwan Fakih, Yun Yen, Jonathan Espejch, Joshua D.L. Ellenbom, Don J. Diamond, and Vincent Chung

4471  Phase I Safety and Pharmacodynamic of Inecalcitol, a Novel VDR Agonist with Docetaxel in Metastatic Castration-Resistant Prostate Cancer Patients
Jacques Medioni, Gael Deplanque, Jean-Marc Ferrero, Tristan Maurina, Jean-Michel P. Rodier, Eric Raymond, Jorge Allyn, Gerard Maruani, Pascal Houllier, Sarah Mackenzie, Stephanie Renaux, Jean-Francois Dufour-Lamartine, Reza Elaidi, Celine Lereis, and Stephane Oudard

PERSONALIZED MEDICINE AND IMAGING

4478  Association of EGFR Expression Level and Cetuximab Activity in Patient-Derived Xenograft Models of Human Non–Small Cell Lung Cancer

4488  Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit
See related commentary, p. 4422
**CANCER THERAPY: PRECLINICAL**

4559  Functional Genetic Approach Identifies MET, HER3, IGF1R, INSR Pathways as Determinants of Lapatinib Unresponsiveness in HER2-Positive Gastric Cancer  
Zhe Zhang, Jiping Wang, Dongmei Ji, Chenchen Wang, Ruijiao Liu, Zheng Wu, Lian Liu, Dan Zhu, Jinjia Chang, Ruixuan Geng, Lei Xiong, Qiangyi Fang, and Jin Li

4574  SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies  
Jutta Deckert, Marie-Cécile Wetzel, Laura M. Bartle, Anna Skaletskaya, Victor S. Golobach, François Vallée, Qing Zhou-Liu, Paul Ferrari, Stéphanie Pouzieux, Charlotte Lahoute, Charles Dumontet, Adriana Plesa, Marielle Chiron, Pascale Lejeune, Thomas Chittenden, Peter U. Park, and Véronique Blanc

**BIOLOGY OF HUMAN TUMORS**

4598  Large-Scale Characterization of DNA Methylation Changes in Human Gastric Carcinomas with and without Metastasis  
Zhaojun Liu, Jun Zhang, Yanhong Gao, Litong Pei, Jing Zhou, Liankun Gu, Lianhai Zhang, Budong Zhu, Naoko Harris, Jiafu Ji, Yasuhiro Yuasa, Wenchao Gou, Zhijian Shu, Huidong Shi, and Dajun Deng

4613  Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers: A Proof-of-Concept Study from BioCAST/IFCT-1002  
Sébastien Couraud, Felipe Vaca-Paniagua, Stéphanie Villar, Javier Oliver, Tibor Schuster, Hélène Blanche, Nicolas Girard, Jean Trédaniel, Laurent Guilleminault, Rajiv Gervais, Nathalie Prim, Michel Vincent, Jacques Margery, Sébastien Larivière, Pascal Foucher, Bernard Duvet, Maxime Vallée, Florence Le Calvez-Kelm, James McKavanagh, Pascale Missy, Franck Morin, Gérard Zalcman, Magali Olivier, and Pierre-Jean Souquet for the BioCAST/IFCT-1002 investigators
Expression of Androgen and Estrogen Signaling Components and Stem Cell Markers to Predict Cancer Progression and Cancer-Specific Survival in Patients with Metastatic Prostate Cancer
Tetsuya Fujimura, Satoru Takahashi, Tomohiko Urano, Kenichi Takayama, Toru Sugihara, Daisuke Obinata, Yuta Yamada, Jimpei Kumagai, Haruki Kame, Yasuyoshi Ouchi, Satoshi Inoue, and Yukio Homma

miR-409-3p/-5p Promotes Tumorigenesis, Epithelial-to-Mesenchymal Transition, and Bone Metastasis of Human Prostate Cancer
Sajni Josson, Murali Gururajan, Peizhen Hu, Chen Shao, Gia Chia-Yi Chu, Haiyen E. Zhuo, Chunyan Liu, Kaiqin Lao, Chia-Lun Lu, Yi-Tsung Lu, Jake Lichterman, Srinivas Nandana, Quanlin Li, Andre Rogatko, Dror Berel, Edwin M. Posadas, Ladan Fazli, Dhruv Sareen, and Leland W.K. Chung

Nondisruptive p53 Mutations Are Associated with Shorter Survival in Patients with Advanced Non–Small Cell Lung Cancer
Miguel A. Molina-Vila, Jordi Bertran-Alamillo, Amaya Gascó, Clara Mayo-de-las-Casas, María Sánchez-Ronco, Laia Pujantell-Pastor, Laura Bonanno, Adolfo G. Favaretto, Andrés F. Cardona, Alain Vergnenègre, Margarita Majem, Bartomeu Massuti, Teresa Morán, Enric Carcereny, Santiago Viteri, and Rafael Rosell
See related commentary, p. 4419

An Integrative Analysis of the Tumorigenic Role of TAZ in Human Non–Small Cell Lung Cancer

To “Grow” or “Go”: TMEM16A Expression as a Switch between Tumor Growth and Metastasis in SCCHN
Daniel J. Shiawski, Chunbo Shao, Anke Bill, John Kim, Dong Xiao, Carol A. Bertrand, Raja S. Seethala, Daisuke Sano, Jeffery N. Myers, Patrick Ha, Jennifer Grandis, L. Alex Gaither, Manojkumar A. Pullenveedu, and Umamaheswar Duvvuri

TMEFF2 Deregulation Contributes to Gastric Carcinogenesis and Indicates Poor Survival Outcome
Tiantian Sun, Wan Du, Hua Xiong, Yanan Yu, Yurong Weng, Linlin Ren, Huijun Zhao, Yingchao Wang, Yingxuan Chen, Jie Xu, Yongbing Xiang, Wenxin Qin, Weibiao Cao, Weiping Zou, Haoyan Chen, Jie Hong, and Jing-Yuan Fang

Decreased Expression of miR216a Contributes to Non–Small-Cell Lung Cancer Progression
Ren-Tao Wang, Meng Xu, Cheng-Xiong Xu, Zhi-Gang Song, and Hua Jin

GSK-3β–Regulated N-Acetyltransferase 10 Is Involved in Colorectal Cancer Invasion
Hong Zhang, Wei Hou, Hua-Li Wang, Hai-Jing Liu, Xin-Ying Jia, Xing-Zheng Zheng, Yong-Xin Zou, Xin Li, Ling Hou, Michael A. McNutt, and Bo Zhang

Downloaded from clin.cancerres.aacrjournals.org on July 15, 2017. © 2014 American Association for Cancer Research.
ABOUT THE COVER

The cover shows the crystal structure of the SAR650984-Fab in complex with human CD38 resolved at 1.53Å resolution. A close-up view of the epitope highlights the interface between human CD38 and SAR650984-Fab, which involves mainly antibody heavy chain CDR loop H3 (yellow) and light chain CDR loops L1, L2 and L3 (green). For details, see the article by Deckert and colleagues on page 4574 of this issue.